animal models of obesity, which translates to a small decrease in excess body weight in humans. [3] [4] [5] [6] Glucagon is a hormone secreted by the α-cells of the pancreas that elevates blood glucose levels by promoting glycogen breakdown and glucose release from hepatocytes. 7 Glucagon also reduces food intake in man, an observation first reported over 50 years ago. 8 Studies in rats indicated that this effect of glucagon is due to increased satiety, by acting directly in the portal venous/hepatic area to decrease meal size. 9 The endogenous dual GLP-1/glucagon receptor agonist, oxyntomodulin, decreased food intake and increased energy expenditure, thus reducing bodyweight by 2.4% following treatment of healthy overweight and obese humans for 4 weeks. [10] [11] [12] [13] [14] The half-life of oxyntomodulin is, however, very short (c. 10 minutes), which precludes its clinical utility. 15 Several reports have recently emerged describing the effects of longer half-life synthetic dual GLP-1/glucagon receptor agonist peptides in rodent models of obesity and diabetes, following the original report from Day et al. (2009) . [16] [17] [18] However, none of these novel analogues has been reported to have advanced to clinical studies to date.
Here we report on the pharmacological properties of MEDI0382 ( Figure 1 ), a novel dual GLP-1/glucagon receptor peptide agonist with a balance of agonism at the GLP-1 and glucagon receptors designed to facilitate both weight loss and glycaemic control, that is currently being developed to treat overweight or obese patients with type 2 diabetes (T2D). 19 The half-life of MEDI0382 has been extended by enhancing stability to peptidase degradation and by palmitoylation to facilitate reversible binding to plasma albumin. 20 and glucagon analogues and pharmacokinetic-pharmacodynamic in vivo screening of peptides with different activity ratios in dietinduced obesity (DIO) mouse models.
| MATERIALS AND METHODS

| Synthesis
MEDI0382 (Figure 1 ) was chemically synthesized. Peptide chain elongation on the resin was performed with the aid of a solid phase peptide synthesizer using manufacturer-supplied protocols for coupling of Fmoc-amino acids. Glutamine residues 20 and 24 were substituted with amino acids that were not susceptible to deamidation and arginine residue 17 was replaced with glutamate to reduce susceptibility to proteolysis. The orthogonal protection of the side chain of Lys10 was removed and the free epsilon-amino group was coupled to gamma-glutamate, followed by palmitic acid to facilitate reversible binding to albumin to extend plasma half-life. GLP-1, oxyntomodulin and glucagon were purchased from Bachem AG (Bubendorf, Switzerland) and liraglutide from PolyPeptide Laboratories (Strasbourg, France). 
| Cyclic AMP accumulation assay
| Glucose-stimulated insulin secretion (GSIS) assay
| Effects in cynomolgus monkeys following repeated administration
Effects of MEDI0382 on food consumption, bodyweight and fasting glucose were assessed in healthy cynomolgus monkeys as part of 4- or 57 (8-week study). Biosystems 5500 mass spectrometer.
| Measurement of peptides
| Measurement of glucose and insulin
Blood was sampled from a tail vein or tail snips in mice and a peripheral vein in monkeys. Blood glucose from tail snips was determined at 3 | RESULTS
| Statistical methods
| MEDI0382 is a potent and selective GLP-1 and glucagon receptor agonist in vitro
The potency (EC 50 ) values for MEDI0382 as measured by cAMP generation in CHO cells over-expressing human recombinant GLP-1 or glucagon receptors in the presence of 0.1% BSA were 6.9 and 10.2 pM, respectively, which were within 10-fold of the native ligands ( Figure 2 and Table 1 ). These potencies were decreased by protein binding when assays were performed in the presence of physiological concentrations of plasma albumin. The potency relative to the native ligands GLP-1 and glucagon is higher for MEDI0382 at the human GLP-1R (1%) than at the human glucagon receptor (0.2%) and this relationship is maintained for mouse, rat and cynomolgus monkey GLP-1 and glucagon receptors ( Table 2 ). MEDI0382 stimulated a concentration-dependent increase in cAMP accumulation in rat (INS-1 832/3) and human (EndoC-βH1) pancreatic β-cell lines as well as rat, mouse and human hepatocytes (Table 1 ). In addition, MEDI0382 potentiated glucose-stimulated insulin secretion in the rat (INS-1 832/3) pancreatic β-cell line and increased glucose output in rat hepatocytes ( Figure 2 and Table 1 ). MEDI0382 showed >10,000-fold selectivity for GLP-1 and glucagon receptor activation over related Class B G protein-coupled receptors such as those for human GIP, GLP-2 and secretin ( Figure S1 , Supporting Information). Values are geometric mean (AE SEM) EC 50 (pM) from n ≥ 3 independent experiments in the presence of 0.1% or 0.2% (GSIS) BSA.
1 GLP-1 = GLP-1 (7-36)NH 2 .
2 GLP-1 = ser8 GLP-1. Values are geometric mean (AE SEM) EC 50 (pM) from n = 4 independent experiments in the presence of 4.4% human albumin, 4.2% monkey albumin, 3.2% mouse albumin or 3.2% rat albumin.
1 GLP-1R activity relative to GLP-1% = (geometric mean EC 50 GLP1/geometric mean EC 50 MEDI0382) × 100. 2 GlucR activity relative to glucagon % = (geometric mean EC 50 glucagon/geometric mean EC 50 MEDI0382) × 100. 3 GlucR/GLP-1R ratio = GlucR activity relative to glucagon %/GLP-1R activity relative to GLP-1%. to lose weight to a greater extent compared to pair-fed mice ( Figure 5A ). MEDI0382 administration was associated with significantly reduced fat mass relative to vehicle and pair-fed groups (p < .05), whereas fat-free mass was not different between groups (data not shown). Indirect calorimetry revealed that VO 2 (rate of oxygen consumption, a proxy for metabolic rate) was elevated in mice dosed with MEDI0382 ( Figure 5B ). Mean 24 hours VO 2 was significantly higher (by 22%, p < .05) relative to vehicle controls, but did not quite reach statistical significance compared to pair-fed controls (15% increase, p = .077, Figure 5C ). The respiratory exchange ratio (RER) was low overall (Figure 5D ), as expected for mice on high-fat diet when fat utilization is forced by the diet. Nevertheless, MEDI0382-treated mice exhibited significantly lower mean 24 hours RER relative to vehicle controls (p < .05), with a strong trend apparent when compared to pair-fed mice (p = .064; Figure 5E ). Analysis of ambulatory activity showed no significant difference in total distance travelled between groups (data not shown).
| Repeated administration of MEDI0382 reduces body weight in cynomolgus monkeys
The terminal plasma half-life of MEDI0382 in cynomolgus monkeys after s.c. administration was measured in a separate single-dose study Values are mean (AE SD); n = 5 male and 5 female animals/group during dosing phase; n = 2 male and 2 female animals/ group during recovery phase. *p < .05; **p < .01; ***p < .001 compared to vehicle.
for males and 5% (9% to 2%), 11% (22% to 4%) and 13% (20% to 6%) of starting body weight for females at dose levels of 8, 16 or Table 1 ). The GLP-1 activity was complemented with glucagon receptor agonist activity in a single peptide to harness the additional effects of glucagon on energy intake, metabolic rate and energy expenditure and hence further reduce bodyweight. [37] [38] [39] [40] This is the first report of the use of more physiologically relevant endogenous receptor systems, namely human and rodent pancreatic (Table 1 ). The relative potency of MEDI0382 in the human and rat pancreatic β-cell lines and hepatocytes when compared to GLP-1, glucagon, oxyntomodulin and liraglutide was, however, similar to that observed in transfected cell lines (Table 1 ). The balance of activity at the GLP-1 and glucagon receptors in humans, determined using transfected cell lines, was confirmed to be biased approximately fivefold towards GLP-1 receptor activation versus glucagon receptor activation (Table 2) and is predicted to provide significant weight loss and glucose control in humans by systems biology modelling of clinical glucagon and GLP-1 data (data not shown). Furthermore, the balance of agonistic activity at each receptor is preserved across species (Table 2) , thus allowing its pharmacology to be evaluated in different preclinical models. 
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